Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675103 · ClinicalTrials.gov registry record · Phase 3
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
A Phase 3 study, sponsored by Savient Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT00675103 is a Phase 3 study that has completed, run by Savient Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT00675103, a Phase 3 study, has completed, sponsored by Savient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry. This study is limited to four study centers in the US.
Interventions
- DRUG pegloticase 8 mg i.v.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00675103
The ClinicalTrials.gov registry entry for NCT00675103 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Savient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pegloticase 8 mg i.v. is the first listed.
NCT00675103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00675103 about?
NCT00675103 is a clinical study titled "Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients". The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v. was at least one year before study entry. This study is limited to four study centers in the US.
What is the current status of trial NCT00675103?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2008-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00675103?
The interventions under investigation include: pegloticase 8 mg i.v. (DRUG).
Who is sponsoring clinical trial NCT00675103?
This trial is sponsored by Savient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.